arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Unicycive Therapeutics, Inc.

UNCY Health Care Biotechnology: Pharmaceutical Preparations
$3.89
▲ +0.5% Today
as of Oct 23, 16:53 ET
Last 30 days -24.47% Sep 14 → Oct 23
$3.22 $3.74 $4.25 $4.77 $5.29 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.95
High
$4.02
Low
$3.71
Volume
$1M
Avg Vol
$843,758
Mkt Cap
$127M
P/E (TTM)
—
Beta
—
52w High
$8.74
52w Low
$3.35
Div Yield
—
Shares Out
$28M

Recent Press Releases & News last 60 days · 6 items

Oct 21 · 21:35 InvestorsHub
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027
Oct 21 · 11:05 PR GlobeNewswire
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Oct 13 · 12:35 Zacks
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
▸ Show all 6 press releases & news Free account →

UNCY earnings at a glance

The options market is pricing a move of about ±39.8% after the report, a range of roughly $2.34 to $5.44 from today's $3.89. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±5.3% on average; after the most recent report on May 12, 2026 it moved +2.8%. That means options currently expect more movement than UNCY has typically delivered. UNCY beat the consensus EPS estimate in 4 of its last 4 reported quarters. Implied volatility is currently 337%. The share price of $3.89 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.35
$8.74
10% of range
Avg surprise (last 4)
+24.7%
Avg reaction (last 2)
-2.6%
50% positive
Latest IV / EM
337%
EM ±39.8% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.50$-1.14$-0.78$-0.41$-0.05 Actual $-0.97Actual $-0.29Actual $-0.13Actual $-0.61Actual $-1.50Actual $-0.46Actual $-0.05Est $-0.08Actual $-0.52Est $-0.70Actual $-0.39Est $-0.59Actual $-0.54Est $-0.55Actual $-0.06 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-13M$-9M$-6M$-3M$598,500 Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.06 — — — — financials
Tue May 12, 2026Mar/2026 $-0.54 $-0.55 +1.8% -980.0% +2.8% earnings
Wed Nov 12, 2025Sep/2025 $-0.39 $-0.59 +33.9% — — earnings
Thu Aug 14, 2025Jun/2025 $-0.52 $-0.70 +25.7% — — earnings
Wed May 14, 2025Mar/2025 $-0.05 $-0.08 +37.5% — -7.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.46 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.50 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.61 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.13 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.29 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.97 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-10M$-8M—$-7M$-7M$-8M—$-6M
Net income$-2M$-13M—$-6M$-6M$570,000—$-4M
EPS (diluted)$-0.06$-0.54—$-0.33$-0.52$-0.50—$-0.46

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$44M$37M$29M$43M$22M$20M$26M—
Inventory————————
Total current assets$71M$64M$49M$50M$30M$27M$31M$38M
Total assets$72M$64M$49M$51M$30M$28M$32M$39M
Long-term debt————————
Total liabilities$19M$27M$19M$13M$14M$17M$24M$11M
Total equity$53M$38M$30M$37M$16M$11M$7M$-28M

Implied volatility — last 90 days

39%131%223%315%407% Jun 08 — IV 188% · EM ±24.8%Jun 09 — IV 202% · EM ±25.3%Jun 10 — IV 121% · EM ±14.3%Jun 11 — IV 135% · EM ±15.0%Jun 12 — IV 101% · EM ±10.3%Jun 15 — IV 67% · EM ±4.9%Jun 16 — IV 407% · EM ±24.1%Jun 17 — IV 196% · EM ±8.2%Jun 19 — IV 244% · EM ±54.0%Jun 22 — IV 242% · EM ±50.5%Jun 23 — IV 266% · EM ±54.4%Jun 24 — IV 302% · EM ±60.6%Jun 25 — IV 275% · EM ±53.8%Jun 26 — IV 317% · EM ±60.7%Jun 29 — IV 283% · EM ±50.2%Jun 30 — IV 114% · EM ±19.6%Jul 01 — IV 106% · EM ±17.7%Jul 02 — IV 214% · EM ±34.7%Jul 03 — IV 226% · EM ±35.3%Jul 06 — IV 108% · EM ±14.9%Jul 07 — IV 114% · EM ±15.1%Jul 08 — IV 114% · EM ±14.3%Jul 09 — IV 101% · EM ±11.9%Jul 10 — IV 104% · EM ±11.5%Jul 13 — IV 112% · EM ±9.3%Jul 14 — IV 159% · EM ±11.5%Jul 15 — IV 126% · EM ±7.5%Jul 16 — IV 142% · EM ±5.9%Jul 20 — IV 101% · EM ±23.9%Jul 21 — IV 106% · EM ±24.6%Jul 22 — IV 104% · EM ±23.8%Jul 23 — IV 114% · EM ±25.6%Jul 24 — IV 111% · EM ±24.5%Jul 27 — IV 105% · EM ±21.9%Jul 28 — IV 99% · EM ±20.2%Jul 29 — IV 96% · EM ±19.2%Jul 30 — IV 93% · EM ±18.3%Jul 31 — IV 99% · EM ±19.0%Aug 03 — IV 99% · EM ±17.5%Aug 04 — IV 93% · EM ±16.0%Aug 05 — IV 103% · EM ±17.2%Aug 06 — IV 92% · EM ±14.9%Aug 07 — IV 133% · EM ±20.7%Aug 10 — IV 108% · EM ±15.0%Aug 11 — IV 99% · EM ±13.1%Aug 12 — IV 96% · EM ±12.1%Aug 13 — IV 102% · EM ±12.0%Aug 14 — IV 115% · EM ±12.7%Aug 17 — IV 269% · EM ±22.4%Aug 18 — IV 321% · EM ±23.2%Aug 19 — IV 364% · EM ±21.5%Aug 20 — IV 395% · EM ±16.5%Aug 24 — IV 81% · EM ±16.9%Aug 25 — IV 78% · EM ±16.0%Aug 26 — IV 93% · EM ±18.6%Aug 27 — IV 102% · EM ±20.0%Aug 28 — IV 72% · EM ±13.8%Aug 31 — IV 68% · EM ±12.0%Sep 01 — IV 78% · EM ±13.4%Sep 02 — IV 66% · EM ±11.1%Sep 03 — IV 64% · EM ±10.4%Sep 04 — IV 62% · EM ±9.7%Sep 07 — IV 70% · EM ±9.7%Sep 08 — IV 79% · EM ±10.4%Sep 09 — IV 66% · EM ±8.3%Sep 10 — IV 100% · EM ±11.8%Sep 11 — IV 98% · EM ±10.9%Sep 15 — IV 205% · EM ±14.9%Sep 16 — IV 159% · EM ±9.4%Sep 17 — IV 226% · EM ±9.4%Sep 21 — IV 83% · EM ±17.4%Sep 22 — IV 69% · EM ±14.1%Sep 23 — IV 67% · EM ±13.5%Sep 24 — IV 64% · EM ±12.5%Sep 25 — IV 86% · EM ±16.5%Sep 28 — IV 70% · EM ±12.4%Sep 29 — IV 159% · EM ±27.4%Sep 30 — IV 105% · EM ±17.6%Oct 01 — IV 39% · EM ±6.4%Oct 02 — IV 133% · EM ±20.7%Oct 06 — IV 148% · EM ±19.5%Oct 07 — IV 344% · EM ±43.1%Oct 08 — IV 337% · EM ±39.8%

Sector peers

SPRB
Spruce Biosciences, Inc.
$129M $45.15+5.7%
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$123M $4.05-5.5%
PMVP
PMV Pharmaceuticals, Inc.
$132M $1.27-6.6%
AARD
Aardvark Therapeutics, Inc.
$115M $1.39-68.5%
LIXT
Lixte Biotechnology Holdings, Inc.
$115M $7.21+75.8%
GNLX
Genelux Corporation
$114M $2.00-3.4%

UNCY earnings FAQ

What is UNCY's expected move for earnings?

Options currently price a move of about ±39.8%, or $1.55 per share either way from $3.89.

How does UNCY stock usually react to earnings?

Across the last 2 reports the average next-day move was ±5.3%, up 1 times and down 1 times.

What is UNCY's implied volatility?

UNCY's at-the-money implied volatility is about 337% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in